pp65 Antigenemia as a Marker of Future CMV Disease and Mortality in HIV-infected Patients
| العنوان: | pp65 Antigenemia as a Marker of Future CMV Disease and Mortality in HIV-infected Patients |
|---|---|
| المؤلفون: | Francisco Gudiol, J. M. Ramón, Miguel Santin, Rogelio Martín, Elena Ferrer, Amparo García, Jordi Niubó, Pérez Jl, Gabriel Rufi, Daniel Podzamczer |
| المصدر: | Scandinavian Journal of Infectious Diseases. 29:223-227 |
| بيانات النشر: | Informa UK Limited, 1997. |
| سنة النشر: | 1997 |
| مصطلحات موضوعية: | Adult, Male, Microbiology (medical), Human cytomegalovirus, medicine.medical_specialty, Adolescent, Congenital cytomegalovirus infection, medicine.disease_cause, Sensitivity and Specificity, Gastroenterology, Herpesviridae, Viral Matrix Proteins, Acquired immunodeficiency syndrome (AIDS), Predictive Value of Tests, Risk Factors, Betaherpesvirinae, Internal medicine, Immunopathology, Humans, Medicine, Sida, Antigens, Viral, Aged, Retrospective Studies, AIDS-Related Opportunistic Infections, General Immunology and Microbiology, biology, business.industry, virus diseases, General Medicine, Middle Aged, Phosphoproteins, biology.organism_classification, medicine.disease, CD4 Lymphocyte Count, Survival Rate, Infectious Diseases, Cytomegalovirus Infections, Cytomegalovirus Retinitis, Immunology, Female, Viral disease, business, Biomarkers |
| الوصف: | We retrospectively evaluated the role of pp65 antigenemia (AGM) as a marker of cytomegalovirus (CMV) disease and mortality in 241 HIV-infected patients with fever. Of 225 patients in whom CD4 count was available, 189 (84%) had counts below 100/microL and 209 (92.8%) below 200/microL, 149 patients had negative AGM (AGM-) and 92 had positive AGM (AGM+), AGM+ patients were at a more advanced stage of HIV disease, as evaluated by CD4 count (p0.001) and prior AIDS diagnosis (p0.001). Overall, 29 patients (12%) presented concomitant CMV disease (18 retinitis): 24 (26%) in the AGM+ group and 5 (3.3%) in the AGM- group (p0.001). AGM had a negative predictive value of 96.6% but a positive predictive value of 26% which increased to 65% if a cut-off of10 CMV-positive cells/10(5) leukocytes was considered. The cumulative rate of future CMV disease at 3 months was 0% in AGM patients, 3% in patients with AGM 1-10/10(5) and 36% in patients with AGM10/10(5). In a multivariate analysis, no antiretroviral therapy, AGM+ and CMV disease were independently associated with mortality. The role of AGM as a marker of present CMV disease is limited. However, quantitative AGM may select patients at a high risk of future CMV disease. In addition, AGM may be a marker of shorter survival in severely immunosuppressed HIV-infected patients. |
| تدمد: | 1651-1980 0036-5548 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20217cd08598a41089ee1554fc77ea2c https://doi.org/10.3109/00365549709019032 |
| رقم الأكسشن: | edsair.doi.dedup.....20217cd08598a41089ee1554fc77ea2c |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 16511980 00365548 |
|---|